Crossmark

Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer

Crossref DOI link: https://doi.org/10.1007/s11912-021-01035-9

Published Online: 2021-03-03

Published Print: 2021-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jiang, Di Maria

Chung, Peter

Kulkarni, Girish S.

James, Nick D.

Sridhar, Srikala S.
License Information

Text and Data Mining valid from 2021-03-01

Version of Record valid from 2021-03-01
More Information

Article History

First Online: 3 March 2021

Declarations

:

: DMJ has no conflict of interest to declare. PC has received honoraria from AbbVie, AstraZeneca, and research funding from Sanofi. GSK has participated in advisory boards for Roche, Merck, Janssen, Theralase, and Ferring; received honoraria from TerSera, Abbvie, and Sanofi; and received funding for clinical trial activities from Astra Zeneca, Merck, BMS, Theralase, and Janssen. NDJ has received consultancy fees from AZ, Merck, and Roche plus trial support from AZ for my RADIO trial. SSS has received compensation from Roche, Merck, Pfizer, Bayer, BMS, Astellas, and AstraZeneca for service as a consultant and has received research funding from Janssen and Sanofi.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below